Arovella Therapeutics Ltd

E4NA

Company Profile

  • Business description

    Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.

  • Contact

    84 Hotham Street
    Corporate One
    PrestonVIC3072
    AUS

    T: +61 398636472

    https://www.arovella.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    44

Stocks News & Analysis

stocks

Plunge in ASX share unwarranted

Weak result distracts from improving trading and cost outlook.
stocks

Oracle shares are up 87% in 2025. Is it a buy?

Oracle’s cloud database business is riding the AI wave.
stocks

Bumper crop to benefit ASX listed share

We raise our earnings forecast 11% for next year.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,137.8014.900.16%
CAC 407,872.0241.910.54%
DAX 4023,611.3384.280.36%
Dow JONES (US)46,292.7888.76-0.19%
FTSE 1009,223.323.36-0.04%
HKSE26,159.12185.02-0.70%
NASDAQ22,573.47215.50-0.95%
Nikkei 22545,493.66447.850.99%
NZX 50 Index13,109.8126.73-0.20%
S&P 5006,656.9236.83-0.55%
S&P/ASX 2008,845.9014.300.16%
SSE Composite Index3,821.836.74-0.18%

Market Movers